Aethlon Receives Ethics Committee Approval For Hemopurifier Cancer Trial In India, Targeting Patients With Solid Tumors Unresponsive To Anti-PD-1 Therapy
Portfolio Pulse from Benzinga Newsdesk
Aethlon Medical has received ethics committee approval to conduct a Hemopurifier cancer trial in India. The trial targets patients with solid tumors unresponsive to anti-PD-1 therapy.
September 19, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aethlon Medical has received ethics committee approval for a cancer trial in India using its Hemopurifier. This trial targets patients with solid tumors unresponsive to anti-PD-1 therapy, potentially expanding Aethlon's market reach and product application.
The approval for the trial in India is a significant step for Aethlon Medical as it expands the potential application of its Hemopurifier. This could lead to increased market opportunities and investor interest, positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100